Unichem Laboratories receives FDA approval on asthma drug
Unichem Laboratories has received the final go ahead from FDA to manufacture the generic version Merck Sharp & Dohme Corp's Singulair tablets. These tablets are used in the treatment of asthma.Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma, as confirmed by the...
Login or Register to read the full article
Unichem Laboratories has received the final go ahead from FDA to manufacture the generic version Merck Sharp & Dohme Corp's Singulair tablets. These tablets are used in the treatment of asthma.
Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma, as confirmed by the PTI.
"The company has received ANDA approval for Motelukast Sodium tablets from the United States Food and Drug Administration (USFDA)," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Goa plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Singulair tablets in the strength of 10 mg, Unichem said.
Montelukast is used for prevention and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis, it added.
Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma, as confirmed by the PTI.
"The company has received ANDA approval for Motelukast Sodium tablets from the United States Food and Drug Administration (USFDA)," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Goa plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Singulair tablets in the strength of 10 mg, Unichem said.
Montelukast is used for prevention and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd